Endocyte Inc.'s shareholders have approved Novartis AG's proposed acquisition of the West Lafayette, Ind., company for $2.1 billion.
The acquisition, expected to close Dec. 21 at $24 per share, received 99.8% of the shareholder votes.
Endocyte specializes in personalized cancer treatments, particularly in prostate cancer. The company has an investigational radioligand therapy, Lu-PSMA-617, in late-stage trials for metastatic castration-resistant prostate cancer.
Previously, Endocyte's board of directors unanimously approved the Swiss company's merger deal.